论文部分内容阅读
本实验利用流体动力学平衡体系（ＨＢＳ）原理，研制了阿司匹林胃漂浮型缓释胶囊（Ａ－ＨＢＳＣ）；并进行了体外溶出速度测定及兔体内药动学研究。Ａ－ＨＢＳＣ的体外溶出属零级动力学过程，Ｋ°ａ＝９．２１％／ｈ（ｔ≤８ｈ）；体内０～８ｈ的吸收速度符合表观零好动力学过程，Ｋ°ａ＝１０．５１％／ｈ；体内外数据具有显著的相关性（ｒ＝０．９９１７，Ｐ＜０．０１）。体内药动学研究表明Ａ－ＨＢＳＣ缓释效果明显，给药后血药浓度较为平缓，持续作用时间长，可减少给药次数；并由于Ａ－ＨＢＳＣ采用轻质辅料具漂浮性能，缓慢释药，有利于降低对胃肠道的刺激性及其它不良反应。
In this study, aspirin floating sustained-release capsules (A-HBSC) were developed by using the principle of fluid dynamic equilibrium system (HBS). The dissolution rate in vitro and the pharmacokinetics in rabbits were studied. In vitro dissolution of A-HBSC is a zero-order kinetic process, K ° a = 9.21% / h (t≤8h); the absorption rate of 0 ~ 8h in vivo accords with the apparent zero good kinetic process, .51% / h. There was a significant correlation between in vivo and in vitro data (r = 0.9917, P <0.01). In vivo pharmacokinetics study showed that A-HBSC slow release effect is obvious after administration of plasma concentration is relatively smooth, long duration of action, can reduce the number of dosing; and A-HBSC with light auxiliary materials with floating performance, slow release , Helps to reduce the gastrointestinal irritation and other adverse reactions.